Therapy Areas
Latest News
Verastem Oncology presents two-year follow-up data on avutometinib and defactinib in recurrent low-grade serous ovarian cancer
10 April 2026 - Biopharmaceutical company Verastem Oncology (Nasdaq:VSTM) on Friday announced two-year median follow-up results from the Phase 2 RAMP 201 clinical trial of Avmapki Fakzynja combination therapy (avutometinib capsules and defactinib tab...
DualityBio reports China NMPA acceptance of BLA for T-Pam for treatment of unresectable or metastatic HER2-positive breast cancer
10 April 2026 - Chinese biopharmaceutical company DualityBio (HK:9606) announced on Thursday that the Biologics License Application (BLA) for the investigational antibody-drug conjugate (ADC) trastuzumab pamirtecan ('T-Pam', also known as D...
Oricell Therapeutics completes USD110m pre-IPO financing
10 April 2026 - Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company developing next-generation cell therapies for oncology and immunology, announced on Thursday the cumulative closing of a pre-IPO financing round in excess o...
Tempus expands oncology collaboration with Gilead to accelerate AI-driven R&D
9 April 2026 - Technology company Tempus AI Inc (NASDAQ:TEM) on Thursday announced an expanded multi-year collaboration with biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) to support the development of Gilead's oncology pipeline.The...
Eli Lilly launches Foundayo weight‑loss pill in the US
...
Solvonis Therapeutics secures second US patent for PTSD compound series
8 April 2026 - Solvonis Therapeutics plc (LSE: SVNS), a biopharmaceutical company developing small-molecule treatments for central nervous system disorders, announced on Wednesday that it has been granted a second US patent (No. 12,595,269) covering ...
GSK secures China approval for Exdensur to treat nasal polyp condition
8 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) revealed on Wednesday that it has received approval from China's National Medical Products Administration for Exdensur (depemokimab) as an add-on treatment for adults with c...